---
document_datetime: 2025-12-02 06:33:54
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/cystagon.html
document_name: cystagon.html
version: success
processing_time: 0.1058888
conversion_datetime: 2025-12-24 21:42:22.872231
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Cystagon

[RSS](/en/individual-human-medicine.xml/66455)

##### Authorised

This medicine is authorised for use in the European Union

mercaptamine bitartrate Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Cystagon](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Cystagon. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Cystagon.

Expand section

Collapse section

## What is Cystagon?

Cystagon is a medicine containing the active substance mercaptamine (also known as cysteamine). It is available as capsules (50 and 150 mg).

## What is Cystagon used for?

Cystagon is used in patients who have nephropathic (kidney) cystinosis. Cystinosis is a rare inherited disease in which excess amounts of cystine, an amino acid naturally found in the body, build up within cells, especially in the kidneys and the eyes, damaging them.

The medicine can only be obtained with a prescription.

## How is Cystagon used?

Cystagon treatment should be started by a doctor who has experience in the treatment of cystinosis.

Cystine levels in white blood cells should be monitored and used to adjust the dose.

For children up to the age of 12 years, the recommended daily dose is calculated according to body surface area (which is calculated from the patient's height and weight), as 1.30 g per m 2 divided into 4 doses. For patients over the age of 12 and over 50 kg in weight, the recommended daily dose is 2 g divided into 4 doses. Starting doses should be one quarter to one sixth of the final expected doses. The starting dose should be increased gradually over 4 to 6 weeks. The maximum dose should never exceed 1.95 g per m 2 per day. For further information, see the package leaflet.

## How does Cystagon work?

The active substance in Cystagon, mercaptamine, reacts with cystine to form another amino acid, called cysteine, and a compound called a cysteine-cysteamine salt. The body is able to remove this salt from the cells. The amount of cystine in the organs is therefore reduced, and this limits the damage to these organs.

## How has Cystagon been studied?

Cystagon has been investigated in three main studies including 234 patients over a 12-year period. These studies included children and newly recruited patients in whom two different doses were tested. Because the disease is very serious, it was not possible for ethical reasons to compare Cystagon directly to placebo (a dummy treatment). The comparison was done instead with a group of patients who had been treated with a dummy treatment as part of another, unrelated trial. The studies looked at the kidney function, the survival and the growth rate of the patients.

## What benefit has Cystagon shown during the studies?

The three studies showed that Cystagon delays kidney problems and the need for dialysis or renal transplantation, when treatment is started at an early age. It also improves survival and growth rate in the children treated.

## What is the risk associated with Cystagon?

The most common side effects with Cystagon (seen in more than 1 patient in 10) are loss of appetite, vomiting, nausea (feeling sick), diarrhoea, lethargy (lack of energy) and pyrexia (fever). For the full list of all side effects reported with Cystagon, see the package leaflet.

Cystagon must not be used in people who are hypersensitive (allergic) to cysteamine or any of the other ingredients, or to another medicine called penicillamine. It should also not be used in women who are breastfeeding, or who are pregnant (particularly during the first three months) unless it is clearly necessary.

## Why has Cystagon been approved?

Cystinosis is a rare, fatal disease, and Cystagon is considered a useful medicine for this disease. The CHMP decided that Cystagon's benefits are greater than its risks and recommended that it be given marketing authorisation.

## Other information about Cystagon

The European Commission granted a marketing authorisation valid throughout the European Union for Cystagon on 23 June 1997.

For more information about treatment with Cystagon, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Cystagon : EPAR - Summary for the public

English (EN) (73.76 KB - PDF)

**First published:** 16/10/2007

**Last updated:** 18/06/2015

[View](/en/documents/overview/cystagon-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-305)

български (BG) (101.33 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

18/06/2015

[View](/bg/documents/overview/cystagon-epar-summary-public_bg.pdf)

español (ES) (96.73 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

18/06/2015

[View](/es/documents/overview/cystagon-epar-summary-public_es.pdf)

čeština (CS) (97.77 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

18/06/2015

[View](/cs/documents/overview/cystagon-epar-summary-public_cs.pdf)

dansk (DA) (72.99 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

18/06/2015

[View](/da/documents/overview/cystagon-epar-summary-public_da.pdf)

Deutsch (DE) (76.83 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

18/06/2015

[View](/de/documents/overview/cystagon-epar-summary-public_de.pdf)

eesti keel (ET) (73.89 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

18/06/2015

[View](/et/documents/overview/cystagon-epar-summary-public_et.pdf)

ελληνικά (EL) (103.98 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

18/06/2015

[View](/el/documents/overview/cystagon-epar-summary-public_el.pdf)

français (FR) (76.55 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

18/06/2015

[View](/fr/documents/overview/cystagon-epar-summary-public_fr.pdf)

hrvatski (HR) (84.9 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

18/06/2015

[View](/hr/documents/overview/cystagon-epar-summary-public_hr.pdf)

italiano (IT) (73.34 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

18/06/2015

[View](/it/documents/overview/cystagon-epar-summary-public_it.pdf)

latviešu valoda (LV) (94.94 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

18/06/2015

[View](/lv/documents/overview/cystagon-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (96.74 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

18/06/2015

[View](/lt/documents/overview/cystagon-epar-summary-public_lt.pdf)

magyar (HU) (94.19 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

18/06/2015

[View](/hu/documents/overview/cystagon-epar-summary-public_hu.pdf)

Malti (MT) (100.16 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

18/06/2015

[View](/mt/documents/overview/cystagon-epar-summary-public_mt.pdf)

Nederlands (NL) (75.56 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

18/06/2015

[View](/nl/documents/overview/cystagon-epar-summary-public_nl.pdf)

polski (PL) (122.19 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

18/06/2015

[View](/pl/documents/overview/cystagon-epar-summary-public_pl.pdf)

português (PT) (76 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

18/06/2015

[View](/pt/documents/overview/cystagon-epar-summary-public_pt.pdf)

română (RO) (95.56 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

18/06/2015

[View](/ro/documents/overview/cystagon-epar-summary-public_ro.pdf)

slovenčina (SK) (99.08 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

18/06/2015

[View](/sk/documents/overview/cystagon-epar-summary-public_sk.pdf)

slovenščina (SL) (90 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

18/06/2015

[View](/sl/documents/overview/cystagon-epar-summary-public_sl.pdf)

Suomi (FI) (74.46 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

18/06/2015

[View](/fi/documents/overview/cystagon-epar-summary-public_fi.pdf)

svenska (SV) (75.01 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

18/06/2015

[View](/sv/documents/overview/cystagon-epar-summary-public_sv.pdf)

## Product information

Cystagon : EPAR - Product Information

English (EN) (545.23 KB - PDF)

**First published:** 16/10/2007

**Last updated:** 11/12/2024

[View](/en/documents/product-information/cystagon-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-331)

български (BG) (638.48 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

11/12/2024

[View](/bg/documents/product-information/cystagon-epar-product-information_bg.pdf)

español (ES) (536.75 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

11/12/2024

[View](/es/documents/product-information/cystagon-epar-product-information_es.pdf)

čeština (CS) (591.14 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

11/12/2024

[View](/cs/documents/product-information/cystagon-epar-product-information_cs.pdf)

dansk (DA) (544.46 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

11/12/2024

[View](/da/documents/product-information/cystagon-epar-product-information_da.pdf)

Deutsch (DE) (554.66 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

11/12/2024

[View](/de/documents/product-information/cystagon-epar-product-information_de.pdf)

eesti keel (ET) (561.49 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

11/12/2024

[View](/et/documents/product-information/cystagon-epar-product-information_et.pdf)

ελληνικά (EL) (615.75 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

11/12/2024

[View](/el/documents/product-information/cystagon-epar-product-information_el.pdf)

français (FR) (546.37 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

11/12/2024

[View](/fr/documents/product-information/cystagon-epar-product-information_fr.pdf)

hrvatski (HR) (605.97 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

11/12/2024

[View](/hr/documents/product-information/cystagon-epar-product-information_hr.pdf)

íslenska (IS) (550.48 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

11/12/2024

[View](/is/documents/product-information/cystagon-epar-product-information_is.pdf)

italiano (IT) (536.42 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

11/12/2024

[View](/it/documents/product-information/cystagon-epar-product-information_it.pdf)

latviešu valoda (LV) (612.02 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

11/12/2024

[View](/lv/documents/product-information/cystagon-epar-product-information_lv.pdf)

lietuvių kalba (LT) (608.53 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

11/12/2024

[View](/lt/documents/product-information/cystagon-epar-product-information_lt.pdf)

magyar (HU) (614.4 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

11/12/2024

[View](/hu/documents/product-information/cystagon-epar-product-information_hu.pdf)

Malti (MT) (638.59 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

11/12/2024

[View](/mt/documents/product-information/cystagon-epar-product-information_mt.pdf)

Nederlands (NL) (547.37 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

11/12/2024

[View](/nl/documents/product-information/cystagon-epar-product-information_nl.pdf)

norsk (NO) (545.8 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

11/12/2024

[View](/no/documents/product-information/cystagon-epar-product-information_no.pdf)

polski (PL) (607.41 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

11/12/2024

[View](/pl/documents/product-information/cystagon-epar-product-information_pl.pdf)

português (PT) (594.27 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

11/12/2024

[View](/pt/documents/product-information/cystagon-epar-product-information_pt.pdf)

română (RO) (610.53 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

11/12/2024

[View](/ro/documents/product-information/cystagon-epar-product-information_ro.pdf)

slovenčina (SK) (598.73 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

11/12/2024

[View](/sk/documents/product-information/cystagon-epar-product-information_sk.pdf)

slovenščina (SL) (595.32 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

11/12/2024

[View](/sl/documents/product-information/cystagon-epar-product-information_sl.pdf)

Suomi (FI) (613.14 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

11/12/2024

[View](/fi/documents/product-information/cystagon-epar-product-information_fi.pdf)

svenska (SV) (542.76 KB - PDF)

**First published:**

16/10/2007

**Last updated:**

11/12/2024

[View](/sv/documents/product-information/cystagon-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IAIN/0074/G 10/12/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Cystagon : EPAR - All Authorised presentations

English (EN) (57.74 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/all-authorised-presentations/cystagon-epar-all-authorised-presentations_en.pdf)

[Other languages (18)](#file-language-dropdown-629)

español (ES) (56.48 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/es/documents/all-authorised-presentations/cystagon-epar-all-authorised-presentations_es.pdf)

čeština (CS) (68.13 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/cs/documents/all-authorised-presentations/cystagon-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (60.12 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/da/documents/all-authorised-presentations/cystagon-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (60.76 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/de/documents/all-authorised-presentations/cystagon-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (50.04 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/et/documents/all-authorised-presentations/cystagon-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (76.21 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/el/documents/all-authorised-presentations/cystagon-epar-all-authorised-presentations_el.pdf)

français (FR) (57.98 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/fr/documents/all-authorised-presentations/cystagon-epar-all-authorised-presentations_fr.pdf)

italiano (IT) (55.78 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/it/documents/all-authorised-presentations/cystagon-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (71.81 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/lv/documents/all-authorised-presentations/cystagon-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (70.42 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/lt/documents/all-authorised-presentations/cystagon-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (72.07 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/hu/documents/all-authorised-presentations/cystagon-epar-all-authorised-presentations_hu.pdf)

Nederlands (NL) (59.64 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/nl/documents/all-authorised-presentations/cystagon-epar-all-authorised-presentations_nl.pdf)

polski (PL) (81.33 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/pl/documents/all-authorised-presentations/cystagon-epar-all-authorised-presentations_pl.pdf)

português (PT) (57.13 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/pt/documents/all-authorised-presentations/cystagon-epar-all-authorised-presentations_pt.pdf)

slovenčina (SK) (80.06 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/sk/documents/all-authorised-presentations/cystagon-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (68.08 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/sl/documents/all-authorised-presentations/cystagon-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (55.28 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/fi/documents/all-authorised-presentations/cystagon-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (59.89 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/sv/documents/all-authorised-presentations/cystagon-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Cystagon Active substance mercaptamine bitartrate International non-proprietary name (INN) or common name mercaptamine bitartrate Therapeutic area (MeSH) Cystinosis Anatomical therapeutic chemical (ATC) code A16AA04

### Pharmacotherapeutic group

Other alimentary tract and metabolism products

### Therapeutic indication

Cystagon is indicated for the treatment of proven nephropathic cystinosis. Cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.

## Authorisation details

EMA product number EMEA/H/C/000125 Marketing authorisation holder

Recordati Rare Diseases

Immeuble le Wilson

Marketing authorisation issued 23/06/1997 Revision 20

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Cystagon : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (167.84 KB - PDF)

**First published:** 16/10/2007

**Last updated:** 11/12/2024

[View](/en/documents/procedural-steps-after/cystagon-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Cystagon : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (104.54 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/steps-after-cutoff/cystagon-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

## Initial marketing authorisation documents

Cystagon : EPAR - Scientific Discussion

English (EN) (177.9 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/scientific-discussion/cystagon-epar-scientific-discussion_en.pdf)

#### More information on Cystagon

- [Cystagon - direct healthcare professional communication (DHPC)](/en/medicines/dhpc/cystagon)
- [A MULTICENTRE, NON-INTERVENTIONAL, RETROSPECTIVE STUDY TO EXPLORE THE EFFECTS OF TRANSITIONING FROM IMMEDIATE RELEASE TO EXTENDED RELEASE ORAL CYSTEAMINE THERAPY IN NORWEGIAN PATIENTS WITH NEPHROPATHIC CYSTINOSIS (CYSTRANSFER) - post-authorisation study](https://catalogues.ema.europa.eu/study/40977)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 11/12/2024

## Share this page

[Back to top](#main-content)